Access the full text.
Sign up today, get DeepDyve free for 14 days.
(1983)Changes in the conditioned emotional response of rats induced by & Delta ; 9 - tetrahydrocannabinol , CBD and mixture of the two cannabinoids
Martin Teicher (1983)Psychiatric Aspects of Neurologic Disease Volume II (Seminars in Psychiatry series)
Journal of Neurology, Neurosurgery & Psychiatry, 46
I. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, E. Carlini (1974)Cannabidiol interferes with the effects of delta 9 - tetrahydrocannabinol in man.
European journal of pharmacology, 28 1
(1976)The development and validation of an experimental portuguese form of the state - trait anxiety inventory
L. Matsuda, S. Lolait, M. Brownstein, A. Young, T. Bonner (1990)Structure of a cannabinoid receptor and functional expression of the cloned cDNA
A. Bond, M. Lader (1974)The use of analogue scales in rating subjective feelings
British Journal of Medical Psychology, 47
(1988)Treatment of anxiety neurosis with ipsapirone
J. Cunha, E. Carlini, A. Pereira, O. Ramos, C. Pimentel, R. Gagliardi, W. Sanvito, N. Lander, R. Mechoulam (1980)Chronic administration of cannabidiol to healthy volunteers and epileptic patients.
Pharmacology, 21 3
(1987)5-HT1a ligand effects in the X-maze anxiety test
D. Wechsler (1955)Manual for the Wechsler Adult Intelligence Scale.
S. Agurell, S. Carlsson, J. Lindgren, A. Ohlsson, H. Gillespie, L. Hollister (1981)Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography.
Experientia, 37 10
F. Guimarães, C. Kohem, G. Gus, H. Fillmann, M. de-Vecino, C. de-Paoli, A. Ribeiro, C. Teixeira, L. Wannmacher (1989)A simple simulated public speaking test for evaluating anxiolytic drugs.
Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 22 9
W. Kostowski, A. Płażnik, R. Stefański (1989)Intra-hippocampal buspirone in animal models of anxiety.
European journal of pharmacology, 168 3
M. Mincis, A. Pfeferman, R. Guimaraes, O. Ramos, E. Zukerman, I. Karniol, E. Carlini (1973)[Chronic administration of cannabidiol in man. Pilot study].
AMB : revista da Associacao Medica Brasileira, 19 5
R. Gillis, Georgetown Univer (1990)Brain 5-HT A receptor agonism: a novel mechanism for antihypertensive action
H. Norris (1971)The action of sedatives on brain stem oculomotor systems in man.
Neuropharmacology, 10 21
P. Saxena, C. Villalón (1990)Brain 5-HT1A receptor agonism: a novel mechanism for antihypertensive action.
Trends in pharmacological sciences, 11 3
A. Zuardi, I. Shirakawa, E. Finkelfarb, I. Karniol (1982)Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.
Psychopharmacology, 76 3
J. Vry, T. Glaser, T. Schuurman, R. Schreiber, J. Traber (1991)5-HT1A Receptors in Anxiety
J. Nye, H. Seltzman, C. Pitt, S. Snyder (1985)High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol.
The Journal of pharmacology and experimental therapeutics, 234 3
J. Deakin, F. Graeff, F. Guimarães (1992)5 ht receptor subtypes and the modulation of aversion
L. Malit, R. Johnstone, D. Bourke, R. Kulp, V. Klein, T. Smith (1975)Intravenous Δ9‐Tetrahydrocannabinol: Effects on Ventilatory Control and Cardiovascular Dynamics
(1976)The neuropsychiatric syndrome of & Delta ; 9 - tetrahydrocannabinol and cannabis intoxication in naive subjects : a clinical and polygraphic study during wakefulness and sleep
M. Herkenham, A. Lynn, Little, J. Mr, L. Melvin, deCosta Br, K. Rice (1990)Cannabinoid receptor localization in brain.
Proceedings of the National Academy of Sciences of the United States of America, 87 5
W. Dalton, R. Martz, L. Lemberger, B. Rodda, R. Forney (1976)Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Clinical Pharmacology & Therapeutics, 19
C. Spielberger, R. Gorsuch, R. Lushene (1970)Manual for the State-Trait Anxiety Inventory
A. Eison, F. Yocca (1985)Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment.
European journal of pharmacology, 111 3
J. Deakin, F. Guimarães, M. Wang, J. Hellewell, R. Hensman (1991)5-HT Receptor Mechanisms in Human Anxiety
(1981)Transcultural evaluation of a self-evaluation scale of subjective states
I. Karniol, E. Carlini (1973)Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol.
Psychopharmacologia, 33 1
J. Gregg, E. Small, R. Moore, D. Raft, T. Toomey (1976)Emotional response to intravenous delta9tetrahydrocannabinol during oral surgery.
Journal of oral surgery, 34 4
M. Rzewuska, K. Sobucka (1993)[Buspirone in the treatment of Generalized Anxiety Disorders].
Psychiatria polska, 27 5
E. Onaivi, M. Green, B. Martin (1990)Pharmacological characterization of cannabinoids in the elevated plus maze.
The Journal of pharmacology and experimental therapeutics, 253 3
K. Goa, A. Ward (1986)Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
Drugs, 32 2
(1989)5 - hydroxytryptamine receptor subtypes and new anxiolytic drugs : an appraisal
E. Schweizer, K. Rickels, G. Warren (1987)Gepirone in Anxiety: A Pilot Study
Journal of Clinical Psychopharmacology, 7
J. Geer (1965)THE DEVELOPMENT OF A SCALE TO MEASURE FEAR.
Behaviour research and therapy, 3
F. Guimarães, A. Zuardi, F. Graeff (1987)Effect of chlorimipramine and maprotiline on experimental anxiety in humans
Journal of Psychopharmacology, 1
(1987)Compounds selective for the 5 HT 1 a receptors have anxiolytic effects when injected into the dorsal raphe nucleus of the rat
P. Consroe, J. Laguna, J. Allender, S. Snider, L. Stern, R. Sandyk, K. Kennedy, K. Schram (1991)Controlled clinical trial of cannabidiol in Huntington's disease
Pharmacology Biochemistry and Behavior, 40
The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STA)). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
Journal of Psychopharmacology – SAGE
Published: Jan 1, 1993
Access the full text.
Sign up today, get DeepDyve free for 14 days.